Skip to content
sellWeak cluster of 2

Mark E. Dmytruk sold $9,060 of DNA

See remarks at Ginkgo Bioworks Holdings, Inc.. 1,244 shares at an average of $7.28, traded Apr 21, 2025, filed Apr 23, 2025.

Warning score
8
Value
$9,060
1,244 shares
Holdings after
45,453
-3% from before
From 52-week low
+32%
low $5.57, close $7.34
From 52-week high
-55%
high $16.36, as of Apr 21, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $9k at market
    0
  • Share of holdings sold
    Sold 2.7% of holdings
    0
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

DNAOct 9, 2026 · close 13.00
Since filing Apr 23, 2025: +71.1%SPY +47.8% · excess +23.2%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001127602-25-012500, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Apr 17, 2025MOption exercise
Class A Common Stock
+454--44,603Apr 23, 2025
Apr 17, 2025MOption exercise
Class A Common Stock
+453--45,056Apr 23, 2025
Apr 17, 2025MOption exercise
Class A Common Stock
+572--45,628Apr 23, 2025
Apr 17, 2025MOption exercise
Class A Common Stock
+1,061--46,689Apr 23, 2025
Apr 17, 2025MOption exercise
Class A Common Stock
+8--46,697Apr 23, 2025
Apr 21, 2025SOpen-market sale
Class A Common Stock
-1,244$7.28$9,06045,453Apr 23, 2025
Apr 17, 2025MOption exercise
Restricted Stock Unitsderivative
-454--4,068Apr 23, 2025
Apr 17, 2025MOption exercise
Restricted Stock Unitsderivative
-453--10,423Apr 23, 2025
Apr 17, 2025MOption exercise
Restricted Stock Unitsderivative
-572--20,060Apr 23, 2025
Apr 17, 2025MOption exercise
Restricted Stock Unitsderivative
-1,061--3,184Apr 23, 2025
Apr 17, 2025MOption exercise
Class B Common Stockderivative
-8--5,906Apr 23, 2025

Related signals

Other insiders at Ginkgo Bioworks Holdings, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
1Weak
DNAsell10b5-1
Ginkgo Bioworks Holdings, Inc.
Steven P. Coen
See remarks
$36k
2,403 shares
-5%
26Weak
DNAsell
Ginkgo Bioworks Holdings, Inc.
Christian O Henry
director
$35k
5,000 shares
-21%
37Weak
DNAsell
Ginkgo Bioworks Holdings, Inc.
Christian O Henry
director
$220k
20,000 shares
-45%
0Weak
DNAsell
Ginkgo Bioworks Holdings, Inc.
Steven P. Coen
See remarks
$3,843
310 shares
-3%
0Weak
DNAsell
Ginkgo Bioworks Holdings, Inc.
Steven P. Coen
See remarks
$11k
1,084 shares
-9%
8Weak
DNAsell 2
Ginkgo Bioworks Holdings, Inc.
Steven P. Coen
See remarks
$2,624
346 shares
-4%
8Weak
DNAsell 2
Ginkgo Bioworks Holdings, Inc.
Mark E. Dmytruk
See remarks
$5,355
706 shares
-2%
13Weak
DNAsell 2
Ginkgo Bioworks Holdings, Inc.
Steven P. Coen
See remarks
$7,261
997 shares
-10%
8Weak
DNAsell 2
Ginkgo Bioworks Holdings, Inc.
Steven P. Coen
See remarks
$3,051
395 shares
-5%
8Weak
DNAsell 2
Ginkgo Bioworks Holdings, Inc.
Mark E. Dmytruk
See remarks
$6,103
790 shares
-2%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Mark E. Dmytruk sold $9,060 of DNA | InsiderTell